Background: Peripheral neuropathy is a common side effect induced by chemotherapy agents like Cisplatin, Paclitaxel andDocetaxel. At present, there is no preventive strategy available against the development of neuropathy. This pilot study wasperformed to evaluate the feasibility of cold therapy and its impact on the incidence and severity of neuropathy induced bypaclitaxel in a dose dense adjuvant regimen among patients with breast cancer. Methods: All adult female patients with early breast cancer planned to be treated with dose-dense schedule of Adriamycin,cyclophosphamide and Paclitaxel were eligible. Ice boot and glove were applied for the duration of all four Paclitaxel infusionson one side while the contralateral limbs were taken as control. Peripheral neuropathy was evaluated and graded prior to eachPaclitaxel infusion and then at 3 and 6 months post treatment. Results: A total of 23 patients were recruited. Cold therapy was found to be feasible as no patient discontinued the ice glove andboot during Paclitaxel infusions. Neuropathy symptoms were observed more frequently and with higher grade of severity oncontrol limbs compared to experimental side. There were 5 patients who were switched to ice glove and boot therapy after theydeveloped peripheral neuropathy in the control limbs. These patients observed improvement in their symptoms subsequently. Conclusion: Cold therapy appears to be feasible and appears to have some potential to prevent Paclitaxel induced peripheralneuropathy in this pilot study. This role of cold therapy may be further explored and confirmed in future randomized trials.
{"title":"The impact of cold therapy on the incidence and severity of paclitaxel induced peripheral neuropathy: A pilot study","authors":"J. Younus, L. Kligman, Dayam Jawaid","doi":"10.5430/JST.V6N2P43","DOIUrl":"https://doi.org/10.5430/JST.V6N2P43","url":null,"abstract":"Background: Peripheral neuropathy is a common side effect induced by chemotherapy agents like Cisplatin, Paclitaxel andDocetaxel. At present, there is no preventive strategy available against the development of neuropathy. This pilot study wasperformed to evaluate the feasibility of cold therapy and its impact on the incidence and severity of neuropathy induced bypaclitaxel in a dose dense adjuvant regimen among patients with breast cancer. Methods: All adult female patients with early breast cancer planned to be treated with dose-dense schedule of Adriamycin,cyclophosphamide and Paclitaxel were eligible. Ice boot and glove were applied for the duration of all four Paclitaxel infusionson one side while the contralateral limbs were taken as control. Peripheral neuropathy was evaluated and graded prior to eachPaclitaxel infusion and then at 3 and 6 months post treatment. Results: A total of 23 patients were recruited. Cold therapy was found to be feasible as no patient discontinued the ice glove andboot during Paclitaxel infusions. Neuropathy symptoms were observed more frequently and with higher grade of severity oncontrol limbs compared to experimental side. There were 5 patients who were switched to ice glove and boot therapy after theydeveloped peripheral neuropathy in the control limbs. These patients observed improvement in their symptoms subsequently. Conclusion: Cold therapy appears to be feasible and appears to have some potential to prevent Paclitaxel induced peripheralneuropathy in this pilot study. This role of cold therapy may be further explored and confirmed in future randomized trials.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"8 1","pages":"43"},"PeriodicalIF":0.0,"publicationDate":"2016-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85084586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and aim: Mortality rates for colorectal cancer have decreased since the mid 1990s. This article provides anup-to-date report on the trends in incidence and survival of colorectal cancer in Canada. In this study we investigate the long-termtrends in the incidence and relative survival ratio of colorectal cancer in Canada over the period of 1992-2008. Patients and methods: Patients with primary colorectal cancer were selected from the Canadian Cancer Registry (CCR) dataset.Patients younger than 18 years of age were excluded. A flexible parametric model was used to estimate two- and five-year relativesurvival ratios and excess mortality rate. Results: In total 159,360 patients with invasive colorectal cancer were identified of which 84,856 (53.2%) were male, 96,495(60.6%) were diagnosed with colon cancer, and 62,865 (39.4%) with the cancer of rectum. Mean age at diagnosis was 68.2 years( SD = 12.1) for men and 70.9 years ( SD = 13.0) for women. The incidence of colorectal cancer remained almost the same formen and women in this period. Except for patients with 70 years and older, two- and five-year relative survival ratios slightlyimproved over time for both sexes. Conclusion: The incidence rate of colorectal cancer remained unchanged and the two- and five-year relative survival ratiossteadily increased for men and women over the study period. Although we used data up to 2008, screening programs in Canadahave been implemented since 2010, therefore, incidence rates may change thereafter and advancements in treatment could furtherimprove the survival of colorectal cancer patients.
{"title":"Long-term trends in the incidence and relative survival of colorectal cancer in Canada: A population-based study","authors":"N. Akhtar-Danesh, G. Akhtar-Danesh, P. Moayyedi","doi":"10.5430/JST.V6N2P35","DOIUrl":"https://doi.org/10.5430/JST.V6N2P35","url":null,"abstract":"Background and aim: Mortality rates for colorectal cancer have decreased since the mid 1990s. This article provides anup-to-date report on the trends in incidence and survival of colorectal cancer in Canada. In this study we investigate the long-termtrends in the incidence and relative survival ratio of colorectal cancer in Canada over the period of 1992-2008. Patients and methods: Patients with primary colorectal cancer were selected from the Canadian Cancer Registry (CCR) dataset.Patients younger than 18 years of age were excluded. A flexible parametric model was used to estimate two- and five-year relativesurvival ratios and excess mortality rate. Results: In total 159,360 patients with invasive colorectal cancer were identified of which 84,856 (53.2%) were male, 96,495(60.6%) were diagnosed with colon cancer, and 62,865 (39.4%) with the cancer of rectum. Mean age at diagnosis was 68.2 years( SD = 12.1) for men and 70.9 years ( SD = 13.0) for women. The incidence of colorectal cancer remained almost the same formen and women in this period. Except for patients with 70 years and older, two- and five-year relative survival ratios slightlyimproved over time for both sexes. Conclusion: The incidence rate of colorectal cancer remained unchanged and the two- and five-year relative survival ratiossteadily increased for men and women over the study period. Although we used data up to 2008, screening programs in Canadahave been implemented since 2010, therefore, incidence rates may change thereafter and advancements in treatment could furtherimprove the survival of colorectal cancer patients.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"258 1","pages":"35"},"PeriodicalIF":0.0,"publicationDate":"2016-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77134907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Troelsen, P. Jørgensen, Steen Baerentzen, T. Baad-Hansen
A 38-year old woman, with a history of monostotic fibrous dysplasia (MFD) of the right femur, developed secondary transformationto both an osteosarcoma and an aneurysmal bone cyst. The patient was initially treated with wide resection and insertion of a hipprosthesis and postoperative chemotherapy. After 3 months she had a recurrence and a hemipelvectomy was performed, followedby a new series of chemotherapy. Seven years after treatment the patient is still alive with no signs of metastasis. It is unknownwhether the osteosarcoma developed from the MFD or from the aneurysmal bone cyst. Secondary transformation of fibrous dysplasia into osteosarcoma is a rare event, especially in MFD without concomitant McCune-Albright syndrome or in patients with MFD without prior radiation therapy. Transformation of an aneurysmal bone cyst is aneven more rare event. This case is reported due to the rare event of malignant transformation of MFD with a concomitant aneurysmal bone cyst and dueto the favorable outcome, in spite of the poor prognosis associated with the condition.
{"title":"Malignant transformation in a patient with fibrous dysplasia and aneurysmal bone cyst","authors":"T. Troelsen, P. Jørgensen, Steen Baerentzen, T. Baad-Hansen","doi":"10.5430/JST.V6N2P30","DOIUrl":"https://doi.org/10.5430/JST.V6N2P30","url":null,"abstract":"A 38-year old woman, with a history of monostotic fibrous dysplasia (MFD) of the right femur, developed secondary transformationto both an osteosarcoma and an aneurysmal bone cyst. The patient was initially treated with wide resection and insertion of a hipprosthesis and postoperative chemotherapy. After 3 months she had a recurrence and a hemipelvectomy was performed, followedby a new series of chemotherapy. Seven years after treatment the patient is still alive with no signs of metastasis. It is unknownwhether the osteosarcoma developed from the MFD or from the aneurysmal bone cyst. Secondary transformation of fibrous dysplasia into osteosarcoma is a rare event, especially in MFD without concomitant McCune-Albright syndrome or in patients with MFD without prior radiation therapy. Transformation of an aneurysmal bone cyst is aneven more rare event. This case is reported due to the rare event of malignant transformation of MFD with a concomitant aneurysmal bone cyst and dueto the favorable outcome, in spite of the poor prognosis associated with the condition.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"127 1","pages":"30"},"PeriodicalIF":0.0,"publicationDate":"2016-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85590139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: To compare the incidence of neutropenia and neutropenic sepsis in Asian versus Caucasian patients with solid tumours onintravenous chemotherapy. Methods: A retrospective case-control study comparing the incidence of neutropenia and neutropenic sepsis in Asian and Caucasian patients receiving infusional chemotherapy at our unit was performed. 15 Asian and 15 Caucasian patients receiving chemotherapy between November 2012 and June 2014 were included in the study and they were matched, where possible, for age, gender, tumour type and chemotherapy regime. The primary objective was to compare the incidence of grade 4 (≤ 0.5 cells x 10 9 /L) neutropenia and neutropenic sepsis. The secondary objective was to compare the incidence of grade 2 (≤ 1.5 cells x 10 9 /L) neutropenia and neutropenic sepsis. Results: There was no significant difference in the proportion of Asian and Caucasian patients who developed grade 4 neutropenia(33.3% vs. 20% of patients; P = .409) or neutropenic sepsis (20% vs. 6.7%; P = .283). However, there was a trend towards agreater proportion of Asian patients developing grade 2 neutropenia (66.7% vs. 33.3%; P = .068) which was associated with asignificantly greater proportion of Asian patients developing grade 2 neutropenic sepsis (40% vs. 6.7%; P = .031). Conclusion: This small-scale study suggests that Asian patients may suffer from an increased propensity towards neutropenia andneutropenic sepsis when receiving infusional chemotherapy emphasising the need for further research in this area. In particular,the role of prophylactic supportive therapy, such as G-CSF, in Asian patients needs to be determined.
目的:比较亚洲人与高加索人静脉化疗实体瘤患者中性粒细胞减少和中性粒细胞减少脓毒症的发生率。方法:回顾性病例对照研究，比较在我单位接受输注化疗的亚裔和白种人患者中性粒细胞减少和中性粒细胞减少脓毒症的发生率。在2012年11月至2014年6月期间接受化疗的15名亚洲患者和15名高加索患者被纳入研究，并在可能的情况下，根据年龄、性别、肿瘤类型和化疗方案进行匹配。主要目的是比较4级(≤0.5个细胞× 10 9 /L)中性粒细胞减少症和中性粒细胞减少性败血症的发生率。次要目的是比较2级(≤1.5个细胞× 10 9 /L)中性粒细胞减少症和中性粒细胞减少性败血症的发生率。结果:亚洲和高加索患者发生4级中性粒细胞减少症的比例无显著差异(33.3% vs 20%;P = .409)或中性粒细胞减少性败血症(20% vs. 6.7%;P = .283)。然而，亚洲患者出现2级中性粒细胞减少症的比例呈上升趋势(66.7% vs. 33.3%;P = 0.068)，这与亚洲患者发生2级中性粒细胞减少性脓毒症的比例显著增加相关(40% vs. 6.7%;P = .031)。结论:这项小规模的研究表明，亚洲患者在接受输注化疗时可能会增加中性粒细胞减少和中性粒细胞减少性败血症的倾向，这强调了在这一领域进一步研究的必要性。特别是，预防性支持疗法，如G-CSF，在亚洲患者中的作用需要确定。
{"title":"Neutropenia in Asian patients with solid tumours receiving chemotherapy: A retrospective case-control study","authors":"N. Dattani, D. Altham, K. Coady","doi":"10.5430/JST.V6N2P25","DOIUrl":"https://doi.org/10.5430/JST.V6N2P25","url":null,"abstract":"Aim: To compare the incidence of neutropenia and neutropenic sepsis in Asian versus Caucasian patients with solid tumours onintravenous chemotherapy. Methods: A retrospective case-control study comparing the incidence of neutropenia and neutropenic sepsis in Asian and Caucasian patients receiving infusional chemotherapy at our unit was performed. 15 Asian and 15 Caucasian patients receiving chemotherapy between November 2012 and June 2014 were included in the study and they were matched, where possible, for age, gender, tumour type and chemotherapy regime. The primary objective was to compare the incidence of grade 4 (≤ 0.5 cells x 10 9 /L) neutropenia and neutropenic sepsis. The secondary objective was to compare the incidence of grade 2 (≤ 1.5 cells x 10 9 /L) neutropenia and neutropenic sepsis. Results: There was no significant difference in the proportion of Asian and Caucasian patients who developed grade 4 neutropenia(33.3% vs. 20% of patients; P = .409) or neutropenic sepsis (20% vs. 6.7%; P = .283). However, there was a trend towards agreater proportion of Asian patients developing grade 2 neutropenia (66.7% vs. 33.3%; P = .068) which was associated with asignificantly greater proportion of Asian patients developing grade 2 neutropenic sepsis (40% vs. 6.7%; P = .031). Conclusion: This small-scale study suggests that Asian patients may suffer from an increased propensity towards neutropenia andneutropenic sepsis when receiving infusional chemotherapy emphasising the need for further research in this area. In particular,the role of prophylactic supportive therapy, such as G-CSF, in Asian patients needs to be determined.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"27 1","pages":"25"},"PeriodicalIF":0.0,"publicationDate":"2016-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83151039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-01Epub Date: 2015-10-14DOI: 10.5430/jst.v6n1p1
Harry Papasozomenos, Nandita Guha-Thakurta, Rory R Mayer, Jeffrey S Weinberg, Morris D Groves, J Matthew Debnam
Objective: Leptomeningeal disease (LMD), the presence of metastasis in the subarachnoid space, has devastating implications if left untreated. The gold standard for LMD diagnosis is cytologic analysis of cerebrospinal fluid (CSF); MRI is also used to evaluate suspected LMD. The purpose of this study was to compare the appearance of LMD in the spinal canal on 18F-FDG PET/CT imaging with the appearance of LMD on MRI and with CSF cytology.
Methods: In twenty-one patients with cytologically-proven spinal LMD, findings on 18F-FDG PET/CT, MRI, and CSF cytology at diagnosis of LMD and after the initiation of treatment for LMD were retrospectively reviewed.
Results: At diagnosis of LMD, abnormal 18F-FDG avidity was demonstrated in the spinal canal in six patients, and the anatomic distribution of 18F-FDG activity corresponded to the sites of LMD on MRI. All six of these patients were then treated with intrathecal chemotherapy. Follow-up 18F-FDG PET/CT and MRI were obtained in four of the six cases. In all four cases, normalization of 18F-FDG activity in the spinal canal and reduction of enhancement on MRI corresponded to the cytologic response to treatment, as determined by CSF analysis.
Conclusion: 18F-FDG avidity in the spinal canal greater than the normal contents of the canal can suggest spinal LMD. This abnormal avidity may be detected before the diagnosis of LMD has been established with MRI or CSF cytology. The spinal canal should be routinely evaluated on 18F-FDG PET/CT in patients with suspected LMD so that appropriate treatment is initiated.
{"title":"Association between <sup>18</sup>F-FDG PET/CT and MRI appearance of spinal leptomeningeal disease before and after treatment at a tertiary referral center.","authors":"Harry Papasozomenos, Nandita Guha-Thakurta, Rory R Mayer, Jeffrey S Weinberg, Morris D Groves, J Matthew Debnam","doi":"10.5430/jst.v6n1p1","DOIUrl":"10.5430/jst.v6n1p1","url":null,"abstract":"<p><strong>Objective: </strong>Leptomeningeal disease (LMD), the presence of metastasis in the subarachnoid space, has devastating implications if left untreated. The gold standard for LMD diagnosis is cytologic analysis of cerebrospinal fluid (CSF); MRI is also used to evaluate suspected LMD. The purpose of this study was to compare the appearance of LMD in the spinal canal on <sup>18</sup>F-FDG PET/CT imaging with the appearance of LMD on MRI and with CSF cytology.</p><p><strong>Methods: </strong>In twenty-one patients with cytologically-proven spinal LMD, findings on <sup>18</sup>F-FDG PET/CT, MRI, and CSF cytology at diagnosis of LMD and after the initiation of treatment for LMD were retrospectively reviewed.</p><p><strong>Results: </strong>At diagnosis of LMD, abnormal <sup>18</sup>F-FDG avidity was demonstrated in the spinal canal in six patients, and the anatomic distribution of <sup>18</sup>F-FDG activity corresponded to the sites of LMD on MRI. All six of these patients were then treated with intrathecal chemotherapy. Follow-up <sup>18</sup>F-FDG PET/CT and MRI were obtained in four of the six cases. In all four cases, normalization of <sup>18</sup>F-FDG activity in the spinal canal and reduction of enhancement on MRI corresponded to the cytologic response to treatment, as determined by CSF analysis.</p><p><strong>Conclusion: </strong><sup>18</sup>F-FDG avidity in the spinal canal greater than the normal contents of the canal can suggest spinal LMD. This abnormal avidity may be detected before the diagnosis of LMD has been established with MRI or CSF cytology. The spinal canal should be routinely evaluated on <sup>18</sup>F-FDG PET/CT in patients with suspected LMD so that appropriate treatment is initiated.</p>","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"6 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5430/jst.v6n1p1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36901197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Tariq, N. Din, Arsalan Ahmed, S. Pervez, Romana Idrees, S. Fatima, M. Umer, N. Kayani
Objective: Parosteal Osteosarcoma (PO) is an uncommon variant of osteosarcoma. Diagnosing PO is important due to itsmalignant nature but the diversity of histologic features makes it challenging by adding a number of soft tissue, bony andcartilaginous lesions into the list of differential diagnosis. Our aim was to study the clinicopathologic and histological features ofPO with emphasis on features helpful in its discrimination from other mimicking lesions. Methods: We reviewed 23 cases of PO diagnosed in our institution between January 2001 and August 2015. Results: Femur was the most commonly involved bone (68.2%) along with other long bones and rib in a single case. Soft tissuecomponent was graded as Grade1 in 9(39%), Grade2 in 8(34.7%) and Grade3 in 4(17.3%) cases. Bony component was seeneither in combination of or exclusively as parallel streams and interconnected trabeculae (mosaic-pattern). Out of 9 cases withcartilage component, 3 showed a cartilage cap. 2(8.6%) cases showed dedifferentiation into osteosarcoma. Conclusion: PO should always be considered in the differential diagnosis of every lesion arising from the bone surface.Knowledge of the variations in histologic features helps to reach the correct diagnosis which should never be made withoutradiological correlation.
{"title":"Challenges and pitfalls in diagnosis of Parosteal Osteosarcoma: A clinicopathologic study of 23 cases","authors":"M. Tariq, N. Din, Arsalan Ahmed, S. Pervez, Romana Idrees, S. Fatima, M. Umer, N. Kayani","doi":"10.5430/JST.V6N2P17","DOIUrl":"https://doi.org/10.5430/JST.V6N2P17","url":null,"abstract":"Objective: Parosteal Osteosarcoma (PO) is an uncommon variant of osteosarcoma. Diagnosing PO is important due to itsmalignant nature but the diversity of histologic features makes it challenging by adding a number of soft tissue, bony andcartilaginous lesions into the list of differential diagnosis. Our aim was to study the clinicopathologic and histological features ofPO with emphasis on features helpful in its discrimination from other mimicking lesions. Methods: We reviewed 23 cases of PO diagnosed in our institution between January 2001 and August 2015. Results: Femur was the most commonly involved bone (68.2%) along with other long bones and rib in a single case. Soft tissuecomponent was graded as Grade1 in 9(39%), Grade2 in 8(34.7%) and Grade3 in 4(17.3%) cases. Bony component was seeneither in combination of or exclusively as parallel streams and interconnected trabeculae (mosaic-pattern). Out of 9 cases withcartilage component, 3 showed a cartilage cap. 2(8.6%) cases showed dedifferentiation into osteosarcoma. Conclusion: PO should always be considered in the differential diagnosis of every lesion arising from the bone surface.Knowledge of the variations in histologic features helps to reach the correct diagnosis which should never be made withoutradiological correlation.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"109 1","pages":"17-24"},"PeriodicalIF":0.0,"publicationDate":"2016-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75025701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and aim: Breast cancer is the commonest malignant tumor and a common cause of cancer death in women all overthe world. Some recent studies attributed breast cancer to viral infection. This study aimed to evaluate the expression of HCMV,EBV and HPV in invasive carcinoma of the breast among the Egyptian women by immunohistochemistry and whether there is arelationship between the prognostic factors of breast carcinoma and these viruses. Patients and methods: This retrospective study included 107 selected cases of invasive breast carcinoma. Slides cut from tissuemicroarray prepared blocks were stained immunohistochemically for HCMV, EBV and HPV antigens. The association of suchviruses with the clinicopathological features, tumor recurrence and patient death was evaluated statistically. Result: HCMV, EBV and HPV were present in 43.9%, 10.3% and 24.3% of cases respectively. HCMV was associatedsignificantly with the tumor grade, mitotic count (P = .01), IDC, ER, PR, Her2/neu and molecular subtype (P = .032, .002, .02,.005, .003) respectively. EBV was associated with the tumor size, stage and histological type (P = . 025, .005, .009) respectively.HPV wasn’t associated with any of the clinicopathological characteristics. None of these viruses was associated with the tumorrecurrence or patient death. Conclusion: HCMV and EBV might be contributing factors for the development and behavioural alteration of breast carcinoma,representing potential tools for the detection of specific therapies for this cancer. Further studies on a larger number of casesusing other techniques such as CISH for specific typing of the viruses especially HPV can add more information.
{"title":"Immunohistochemical detection of human cytomegalovirus, Epstein-Barr virus and human papillomavirus in invasive breast carcinoma in Egyptian women: A tissue microarray study","authors":"R. Ahmed, S. Yussif","doi":"10.5430/JST.V6N2P8","DOIUrl":"https://doi.org/10.5430/JST.V6N2P8","url":null,"abstract":"Background and aim: Breast cancer is the commonest malignant tumor and a common cause of cancer death in women all overthe world. Some recent studies attributed breast cancer to viral infection. This study aimed to evaluate the expression of HCMV,EBV and HPV in invasive carcinoma of the breast among the Egyptian women by immunohistochemistry and whether there is arelationship between the prognostic factors of breast carcinoma and these viruses. Patients and methods: This retrospective study included 107 selected cases of invasive breast carcinoma. Slides cut from tissuemicroarray prepared blocks were stained immunohistochemically for HCMV, EBV and HPV antigens. The association of suchviruses with the clinicopathological features, tumor recurrence and patient death was evaluated statistically. Result: HCMV, EBV and HPV were present in 43.9%, 10.3% and 24.3% of cases respectively. HCMV was associatedsignificantly with the tumor grade, mitotic count (P = .01), IDC, ER, PR, Her2/neu and molecular subtype (P = .032, .002, .02,.005, .003) respectively. EBV was associated with the tumor size, stage and histological type (P = . 025, .005, .009) respectively.HPV wasn’t associated with any of the clinicopathological characteristics. None of these viruses was associated with the tumorrecurrence or patient death. Conclusion: HCMV and EBV might be contributing factors for the development and behavioural alteration of breast carcinoma,representing potential tools for the detection of specific therapies for this cancer. Further studies on a larger number of casesusing other techniques such as CISH for specific typing of the viruses especially HPV can add more information.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"119 1","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2016-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77582409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To assess the efficacy, side effects and progression-free interval of a modified regimen of the combination ofgemcitabine and cisplatin among women with recurrent epithelial ovarian cancer. Methods: Twenty-eight women with recurrent epithelial ovarian, primary peritoneal or fallopian tube cancers were treated withgemcitabine (500 mg/m 2 ) followed by cisplatin (50 mg/m 2 ) on days one and eight every three weeks. Patients’ demographics,response, side effects, and progression-free interval were recorded. Result: The median age of patients was 61 (range 44-74 years). Twenty-three (82.1%) patients had platinum-sensitive and five(17.9%) had platinum-resistant tumors. The median number of prior chemotherapy regimens was two (range 1-4) and ninepatients had > three prior regimens. The median number of cycles was six (range 2-10). Seventeen (60.7%) patients respondedto chemotherapy (11 complete and six partial), six had stable disease and five had progression. The response rate was 69.6%and 20% among women with platinum-sensitive and platinum-resistant tumors, respectively ( P = .024). The median (range)progression-free interval was six (2-12) and nine (4-12) months among all patients and patients who responded to chemotherapy,respectively. Four patients had dose reductions, four had delays and three had their chemotherapy terminated secondary to toxicityor patient desire. There were no chemotherapy-related mortality or hospital admissions. The incidence of grade 3-4 neutropenia,anemia, thrombocytopenia, and nausea or vomiting was 32.1%, 10.7%, 35.7%, and 10.7%, respectively. Conclusion: The combination gemcitabine and cisplatin is highly effective among women with recurrent ovarian cancerincluding those who are heavily pre-treated and is reasonably tolerated. Although, the combination is effective among womenwith plantinum-resistant tumors, these women have a lower response than women with platinum-sensitive tumors.
{"title":"Efficacy of a modified regimen of gemcitabine and cisplatin among women with recurrent epithelial ovarian cancer","authors":"G. Eltabbakh, E. Donovan, G. D. Eltabbakh","doi":"10.5430/JST.V6N2P1","DOIUrl":"https://doi.org/10.5430/JST.V6N2P1","url":null,"abstract":"Objective: To assess the efficacy, side effects and progression-free interval of a modified regimen of the combination ofgemcitabine and cisplatin among women with recurrent epithelial ovarian cancer. Methods: Twenty-eight women with recurrent epithelial ovarian, primary peritoneal or fallopian tube cancers were treated withgemcitabine (500 mg/m 2 ) followed by cisplatin (50 mg/m 2 ) on days one and eight every three weeks. Patients’ demographics,response, side effects, and progression-free interval were recorded. Result: The median age of patients was 61 (range 44-74 years). Twenty-three (82.1%) patients had platinum-sensitive and five(17.9%) had platinum-resistant tumors. The median number of prior chemotherapy regimens was two (range 1-4) and ninepatients had > three prior regimens. The median number of cycles was six (range 2-10). Seventeen (60.7%) patients respondedto chemotherapy (11 complete and six partial), six had stable disease and five had progression. The response rate was 69.6%and 20% among women with platinum-sensitive and platinum-resistant tumors, respectively ( P = .024). The median (range)progression-free interval was six (2-12) and nine (4-12) months among all patients and patients who responded to chemotherapy,respectively. Four patients had dose reductions, four had delays and three had their chemotherapy terminated secondary to toxicityor patient desire. There were no chemotherapy-related mortality or hospital admissions. The incidence of grade 3-4 neutropenia,anemia, thrombocytopenia, and nausea or vomiting was 32.1%, 10.7%, 35.7%, and 10.7%, respectively. Conclusion: The combination gemcitabine and cisplatin is highly effective among women with recurrent ovarian cancerincluding those who are heavily pre-treated and is reasonably tolerated. Although, the combination is effective among womenwith plantinum-resistant tumors, these women have a lower response than women with platinum-sensitive tumors.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"34 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2016-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74049164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bo Chen, Honggang Zhou, Wei Wang, Wen-guang Gu, Dong Zhao, Peng-Lai Wang
In this study, in vitro (21 kinds of cell lines) and in vivo (four kinds of tumor-bearing mouse models) experiments were performedto determine the anticancer effect of doxycycline. This drug may elicit a strong inhibitory effect on cancer cells and improve thesurvival condition of mice. This study also preliminarily investigated the inhibitory effect of doxycycline on different kinds oftumor cells.
{"title":"Studies on antitumor activity spectrum of doxycycline","authors":"Bo Chen, Honggang Zhou, Wei Wang, Wen-guang Gu, Dong Zhao, Peng-Lai Wang","doi":"10.5430/JST.V6N1P103","DOIUrl":"https://doi.org/10.5430/JST.V6N1P103","url":null,"abstract":"In this study, in vitro (21 kinds of cell lines) and in vivo (four kinds of tumor-bearing mouse models) experiments were performedto determine the anticancer effect of doxycycline. This drug may elicit a strong inhibitory effect on cancer cells and improve thesurvival condition of mice. This study also preliminarily investigated the inhibitory effect of doxycycline on different kinds oftumor cells.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"2 1","pages":"103"},"PeriodicalIF":0.0,"publicationDate":"2016-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79270571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Many febrile neutropenic patients (FNP) with solid tumors receive high dose antibacterial therapy adequate forP. aeruginosa infections. This study was designed to determine the frequency of P. aeruginosa infections in FNP with solidneoplasms and detect any differences in duration of fever, length of stay (LOS) and deaths of patients receiving low (LD) vs. highdose (HD) antibacterial therapy. Methods: Electronic medical record databases were searched to identify patients with drug-induced neutropenia and fever. Theresulting data was searched manually for patients with solid neoplasms and these charts were selected consecutively for manualreview for additional inclusion criteria, comparison characteristics, such as type of neoplasm, comorbidities, potential risk factorssuch as duration of neutropenia, documented infections, and outcomes: duration of temperature to < 37.5℃ and < 38℃ , lengthof stay (LOS), and cause of death. Components of the Multinational Association for Supportive Care of Cancer risk index(MASCCRI) were extracted and the index was calculated for each episode. Results: The respective outcomes of LD vs. HD were: mean duration of temperature to < 38℃, 3 vs. 3 days, and to < 37.5℃, 4vs. 4 days, mean LOS 6.3 vs. 6.6 days (p = .56, TT; but p < .01, WRST), and LOS 10 days , 90% vs. 89%, Zero vs. 2 developedP. aeruginosa infections. Conclusions: LD antibacterials for FNP with solid neoplasms did not prolong the time to afebrile or the LOS, and only 2 P.aeruginosa infections occurred. High dose antibacterial therapy may not be necessary for FNP with solid neoplasms.
背景:许多发热性中性粒细胞减少患者(FNP)合并实体瘤接受足够的高剂量抗菌治疗。绿脓杆菌感染。本研究旨在确定伴有固体性肿瘤的FNP患者铜绿假单胞菌感染的频率，并检测接受低剂量(LD)与高剂量(HD)抗菌治疗的患者在发烧持续时间、住院时间(LOS)和死亡人数方面的差异。方法:检索电子病历数据库，对药物性中性粒细胞减少和发热患者进行识别。对实体肿瘤患者的数据进行人工检索，并连续选择这些图表进行人工审查，以获得额外的纳入标准、比较特征，如肿瘤类型、合并症、潜在危险因素，如中性粒细胞减少持续时间、记录的感染，以及结果:温度< 37.5℃和< 38℃的持续时间、住院时间(LOS)和死亡原因。提取多国癌症支持治疗协会风险指数(MASCCRI)的组成部分，并计算每个事件的指数。结果:LD与HD的结果分别为:平均温度降至< 38℃持续时间3天vs. 3天，降至< 37.5℃持续时间4天。4天，平均LOS 6.3天和6.6天(p = 0.56, TT;但p < 0.01, WRST)和LOS 10天，90% vs 89%， 0 vs 2发展p。绿脓杆菌感染。结论:对于合并实体瘤的FNP患者，使用LD抗菌药不延长其发热时间和LOS，仅发生2例铜绿假单胞菌感染。对于伴有实体肿瘤的FNP可能不需要大剂量抗菌治疗。
{"title":"Febrile neutropenic patients with solid neoplasms have few P. aeruginosa infections and higher antibacterial doses showed no benefit over lower doses","authors":"R. Bitar","doi":"10.5430/JST.V6N1P94","DOIUrl":"https://doi.org/10.5430/JST.V6N1P94","url":null,"abstract":"Background: Many febrile neutropenic patients (FNP) with solid tumors receive high dose antibacterial therapy adequate forP. aeruginosa infections. This study was designed to determine the frequency of P. aeruginosa infections in FNP with solidneoplasms and detect any differences in duration of fever, length of stay (LOS) and deaths of patients receiving low (LD) vs. highdose (HD) antibacterial therapy. Methods: Electronic medical record databases were searched to identify patients with drug-induced neutropenia and fever. Theresulting data was searched manually for patients with solid neoplasms and these charts were selected consecutively for manualreview for additional inclusion criteria, comparison characteristics, such as type of neoplasm, comorbidities, potential risk factorssuch as duration of neutropenia, documented infections, and outcomes: duration of temperature to < 37.5℃ and < 38℃ , lengthof stay (LOS), and cause of death. Components of the Multinational Association for Supportive Care of Cancer risk index(MASCCRI) were extracted and the index was calculated for each episode. Results: The respective outcomes of LD vs. HD were: mean duration of temperature to < 38℃, 3 vs. 3 days, and to < 37.5℃, 4vs. 4 days, mean LOS 6.3 vs. 6.6 days (p = .56, TT; but p < .01, WRST), and LOS 10 days , 90% vs. 89%, Zero vs. 2 developedP. aeruginosa infections. Conclusions: LD antibacterials for FNP with solid neoplasms did not prolong the time to afebrile or the LOS, and only 2 P.aeruginosa infections occurred. High dose antibacterial therapy may not be necessary for FNP with solid neoplasms.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"28 1","pages":"94"},"PeriodicalIF":0.0,"publicationDate":"2016-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74881816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：